Watch ZBH. Know when insiders buy.
One email the day a filing lands. Free.
ZBH
ZIMMER BIOMET HOLDINGS, INC.
94.86
−1.14 −1.19%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · insiders 27, shorts 50
Insiders, 90 days
−$824K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $18.1BP/E 23.0DIV YIELD 1.01%FCF YIELD 8.42%REV TTM $8.5B +8.6%NET INCOME $806.6M −2.0%NET DEBT $590M52W 79.58 – 103.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $2.2B | +4.8% | 70.8% | $326.1M | $198.3M | +29.8% | 1.03 | $447.8M | $54.2M | $393.6M | Aug 5 |
| Q1 2026 · Mar 31 | $2.1B | +9.3% | 72.4% | $373.2M | $238.1M | +30.8% | 1.22 | $359.4M | $36.3M | $323.1M | May 1 |
| Q4 2025 · Dec 31derived | $2.2B | +10.9% | 64.7% | $154.5M | $139.3M | −41.8% | 0.71 | $517.4M | $74.8M | $442.6M | Feb 20 |
| Q3 2025 · Sep 30 | $2B | +9.7% | 72.1% | $351.3M | $230.9M | −7.3% | 1.16 | $418.7M | $55M | $363.7M | Nov 5 |
| Q2 2025 · Jun 30 | $2.1B | +7.0% | 71.5% | $300M | $152.8M | −37.1% | 0.77 | $378.2M | $50.1M | $328.1M | Aug 5 |
| Q1 2025 · Mar 31 | $1.9B | +1.1% | 71.2% | $292.3M | $182M | +5.6% | 0.91 | $382.8M | $44.6M | $338.2M | May 1 |
| Q4 2024 · Dec 31derived | $2B | +4.3% | 71.0% | $389M | $239.5M | −42.9% | 1.19 | $506.3M | $51.5M | $454.8M | Feb 20 |
| Q3 2024 · Sep 30 | $1.8B | +4.0% | 70.5% | $279.5M | $249.1M | +53.1% | 1.23 | $395.7M | $44.5M | $351.2M | Nov 5 |
| Q2 2024 · Jun 30 | $1.9B | — | 71.5% | $351.3M | $242.8M | — | 1.18 | $369.4M | $52.7M | $316.7M | Aug 7 |
| Q1 2024 · Mar 31 | $1.9B | — | 72.9% | $265.9M | $172.4M | — | 0.84 | $228M | $55.1M | $172.9M | May 5 |
| Q4 2023 · Dec 31derived | $1.9B | — | 72.2% | $354.2M | $419.2M | — | 2.00 | $588.4M | $62.8M | $525.6M | Feb 20 |
| Q3 2023 · Sep 30 | $1.8B | — | 70.4% | $266.6M | $162.7M | — | 0.77 | $337.6M | $84.3M | $253.3M | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $8.2B | 69.7% | $1.1B | $705.1M | 8.6% | 3.55 | $1.7B | $224.5M | $1.5B | $487M | $190.3M |
| FY2024 · to Dec 31 | $7.7B | 71.5% | $1.3B | $903.8M | 11.8% | 4.43 | $1.5B | $203.8M | $1.3B | $868M | $196M |
| FY2023 · to Dec 31 | $7.4B | 71.8% | $1.3B | $1B | 13.8% | 4.88 | $1.6B | $291.1M | $1.3B | $692.2M | $200.9M |
| FY2022 · to Dec 31 | $6.9B | 70.9% | $696.3M | $231.4M | 3.3% | 1.10 | $1.4B | $187.9M | $1.2B | $126.4M | $201.2M |
| FY2021 · to Dec 31 | $6.8B | 71.3% | $860.3M | $401.6M | 5.9% | 1.91 | $1.5B | $143.6M | $1.4B | — | $200.1M |
| FY2020 · to Dec 31 | $6.1B | 70.2% | $83.1M | −$138.9M | -2.3% | -0.67 | $1.2B | $111.9M | $1.1B | — | $198.5M |
Every number comes from ZIMMER BIOMET HOLDINGS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.